The U of Nebraska recently started a clinical trial to evaluate Gilead's Remdesivir to treat COVID-19, sponsored by the National Institutes of Health (NIH/NIAID).
However, it has not proven to be beneficial yet:
"“We urgently need a safe and effective treatment for COVID-19. Although Remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes,” said NIAID Director and U.S. Coronavirus Task Force member Anthony S. Fauci, M.D."
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins
Contrast that with Mesoblast's statement today (excerpt):
"Remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19
infection. This is supported by recently published results from an investigator-initiated clinical study conducted in
China which reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated
patients with severe COVID-19 pneumonia."
My conclusion:
1) Dr. Itescu would not release today's PR unless he is pretty sure Remestemcel-L works. I believe he is not trying to simply get on the COVID-19 cure bandwagon to gain market attention. The man is conservative.
2) Gilead's Remdesivir is unproven so far, from Anthony Fauci's statement.
Advantage Mesoblast.
- Forums
- ASX - By Stock
- MSB
- Gilead vs Mesoblast
Gilead vs Mesoblast
-
-
- There are more pages in this discussion • 274 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 18069 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9996 | 0.990 |
2 | 32880 | 0.985 |
4 | 71034 | 0.980 |
2 | 3059 | 0.975 |
7 | 145890 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 1132 | 1 |
1.000 | 9500 | 3 |
1.005 | 35000 | 1 |
1.010 | 58113 | 4 |
1.015 | 46100 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online